Wellfully (ASX:WFLOA) ROE % Adjusted to Book Value: Negative Equity% (As of Dec. 2023)


What is Wellfully ROE % Adjusted to Book Value?

Wellfully ASX:WFLOA ROE % Adjusted to Book Value is Negative Equity% as of Dec. 2023. The stock has 7 warning signs investors should review.

Wellfully's ROE % for the quarter that ended in Dec. 2023 was Negative Equity. Wellfully's PB Ratio for the quarter that ended in Dec. 2023 was N/A. Wellfully's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was Negative Equity.

Wellfully ROE % Adjusted to Book Value Related Terms

Wellfully ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Wellfully's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wellfully ROE % Adjusted to Book Value Chart

Wellfully Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Wellfully Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 Negative Equity

ASX:WFLOA vs TMO, DHR, IDXX: ROE % Adjusted to Book Value Comparison

For the Diagnostics & Research subindustry, Wellfully's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wellfully ROE % Adjusted to Book Value vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Wellfully's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Wellfully's ROE % Adjusted to Book Value falls into.


Wellfully ROE % Adjusted to Book Value Calculation

Wellfully's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Wellfully's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
Wellfully (ASX:WFLOA) has a ROE % Adjusted to Book Value of Negative Equity% as of Dec. 2023. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Wellfully and its competitors.
Is Wellfully's ROE % Adjusted to Book Value too high?
Wellfully's current ROE % Adjusted to Book Value is Negative Equity%.
How does Wellfully's ROE % Adjusted to Book Value compare to TMO and DHR?
Wellfully's ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Diagnostics & Research company?
A good ROE % Adjusted to Book Value depends on the Medical Diagnostics & Research industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Wellfully and its competitors. Wellfully's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wellfully stock overvalued right now?
Wellfully (ASX:WFLOA) has a current ROE % Adjusted to Book Value of Negative Equity%. The current ROE % Adjusted to Book Value is Negative Equity%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Wellfully (ASX:WFLOA), the current ROE % Adjusted to Book Value is Negative Equity% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wellfully Business Description

Address 284 Oxford Street, Ground Floor, Leederville, WA, AUS, 6007
Wellfully Ltd is engaged in the research and development of Dermaportation and ETP transdermal drug delivery technologies. The company operates in segments namely the development of the dermaportation drug delivery technology and Devices segments. Geographically, it derives a majority of its revenue from Europe and also has a presence in Japan. It serves the Pharmaceutical; Cosmetics Skincare and Consumer Healthcare industries.